Trial · NCT01504412
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | Placebo | Baseline to Week 1 | -0.59 | Standard Deviation 1.13 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | Pregabalin | Baseline to Week 1 | -0.71 | Standard Deviation 1.29 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 10 mg/Day | Baseline to Week 1 | -0.69 | Standard Deviation 0.90 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 20 mg/Day | Baseline to Week 1 | -0.88 | Standard Deviation 1.32 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 30 mg/Day | Baseline to Week 1 | -0.60 | Standard Deviation 1.01 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | Placebo | Baseline to Week 2 | -0.86 | Standard Deviation 1.36 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | Pregabalin | Baseline to Week 2 | -0.92 | Standard Deviation 1.33 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 10 mg/Day | Baseline to Week 2 | -1.16 | Standard Deviation 1.06 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 20 mg/Day | Baseline to Week 2 | -1.21 | Standard Deviation 1.56 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 30 mg/Day | Baseline to Week 2 | -1.06 | Standard Deviation 1.28 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | Placebo | Baseline to Week 3 | -1.05 | Standard Deviation 1.38 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | Pregabalin | Baseline to Week 3 | -1.06 | Standard Deviation 1.29 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 10 mg/Day | Baseline to Week 3 | -1.32 | Standard Deviation 1.15 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 20 mg/Day | Baseline to Week 3 | -1.50 | Standard Deviation 1.68 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 30 mg/Day | Baseline to Week 3 | -1.35 | Standard Deviation 1.52 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | Placebo | Baseline to Week 4 | -1.12 | Standard Deviation 1.47 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | Pregabalin | Baseline to Week 4 | -1.29 | Standard Deviation 1.48 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 10 mg/Day | Baseline to Week 4 | -1.50 | Standard Deviation 1.22 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 20 mg/Day | Baseline to Week 4 | -1.65 | Standard Deviation 1.68 | units on a scale |
| Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy | DS-5565 30 mg/Day | Baseline to Week 4 | -1.56 | Standard Deviation 1.53 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01504412/results